RxDoctor Payments Data

Carmen Pagan Duran, MD

Rheumatology · San Juan, PRNPI 1518916295

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.3% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Amgen at 47.4% of the total. That places this record below the midpoint for rheumatology clinicians in PR, where the typical reported total is $2,108.

$1,305in general payments, 2019–2025

Across 52 payments — averaging $25.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$619
  • Johnson & Johnson$276
  • AbbVie$82
  • ANI Pharmaceuticals, Inc.$80
  • E.r. Squibb & Sons, L.L.C.$61
  • Organon$49
  • plus $139 from 6 others
$17in research payments, 2019–2025

Across 1 payment — averaging $17.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$17

What the payments were for

  • Food & beverage$1,19291%
  • Education$1139%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,305 in reported general payments places this provider in the 35th percentile of 88 rheumatology providers in Puerto Rico.

See all rheumatology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$17,738
Medicare patients
45
Services billed
146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydroxychloroquine Sulfate37$1,492
Diclofenac Sodium11$1,346
MethotrexateMethotrexate Sodium49$959
Colchicine15$661
Prednisone93$515
Sulfasalazine16$491
Diclofenac Potassium16$373
Allopurinol12$209
Alendronate Sodium29$173
Gabapentin14$162
Naproxen20$161
Methylprednisolone17$136
Meloxicam37$91

Paid to pharmacies, not to this prescriber.

Other rheumatology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →